Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01889186 · ClinicalTrials.gov registry record · Phase 2
A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion
A Phase 2 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 2
- Development phase
- 158
- Enrollment target
NCT01889186 is a Phase 2 study that has completed, run by AbbVie. The registered enrollment target is 158 participants.
The verdict
NCT01889186, a Phase 2 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 158 participants
- Enrollment target
Study Summary
This was an open-label, multicenter, global study to determine the efficacy of ABT-199 (Venetoclax) monotherapy in participants with relapsed/refractory (R/R) or previously untreated chronic lymphocytic leukemia (CLL) harboring 17p deletion.
Interventions
- DRUG ABT-199 (Main Cohort)
- DRUG ABT-199 (Safety Expansion Cohort)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2013-06-27 |
| Est. Completion | 2020-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01889186
The ClinicalTrials.gov registry entry for NCT01889186 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ABT-199 (Main Cohort) is the first listed.
NCT01889186 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01889186 about?
NCT01889186 is a clinical study titled "A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion". This was an open-label, multicenter, global study to determine the efficacy of ABT-199 (Venetoclax) monotherapy in participants with relapsed/refractory (R/R) or previously untreated chronic lymphocytic leukemia (CLL) harboring 17p deletion.
What is the current status of trial NCT01889186?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 158 participants. The study started on 2013-06-27. Estimated completion is 2020-12-15.
What interventions are being tested in trial NCT01889186?
The interventions under investigation include: ABT-199 (Main Cohort) (DRUG), ABT-199 (Safety Expansion Cohort) (DRUG).
Who is sponsoring clinical trial NCT01889186?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.